Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

OT-II mice

The Increasing CD4+T/CD8+T Cells Ratio OT-II mice exhibit a significant shift in their T cell population, with increasing in the CD4+/CD8+ T cell ratio compared to wild-type mice. The CD4+/CD8 ratio between wild-type C57BL/6JNifdc mice and homozygous OT-II mic

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The Increasing CD4+T/CD8+T Cells Ratio

  • OT-II mice exhibit a significant shift in their T cell population, with increasing in the CD4+/CD8+ T cell ratio compared to wild-type mice.

The CD4+/CD8 ratio between wild-type C57BL/6JNifdc mice and homozygous OT-II mice. Splenocytes, blood and lymph nodes were collected from wild-type C57BL/6JNifdc mice and homozygous OT-II mice (male, 7-week-old).

TCR Vα2 and Vβ5 Protein Expression Analysis

  • The mouse TCR Vα2+TCR Vβ5+ cells were exclusively detectable in homozygous OT-II mice.

Strain specific mouse TCR Vα2 and TCR Vβ5 expression analysis in wild-type C57BL/6JNifdc mice and homozygous B-OT-II mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6JNifdc mice (+/+) and homozygous OT-II mice (H/H), and analyzed by flow cytometry with species-specific anti-mTCR Vα2 antibody (Biolegend, 127807) and anti-mTCR Vβ5.1, 5.2  antibody (Biolegend, 139505).

Antigen-specific Activation

  • Flow cytometry analyses of OVA323–339 challenged CD4+ T cells from OT-II mice showed higher surface expression levels of the early T cell activation markers CD69 and CD25.

Antigen-specific activation increases surface CD25 and CD69 expression of OT-II CD4+ T cells. Splenocytes from wild-type C57BL/6JNifdc mice and homozygous OT-II mice were exposed for 24h to OVA323-339. In parallel, medium and OVA257-264 (10 µg/mL) were included as negative controls. And anti-mCD3e mAb were included positive controls. Percentage of CD25+ (A) and CD69+ (B) gated CD4+ T-cells were assessed by flow cytometry. Data are mean ± SEM values.

Antigen-specific Activation Increases IL-2 Expression

  • ELISA analysis of culture supernatants from OVA323-339-challenged (10 µg/mL) OT-II mice splenocytes for 24h revealed increased levels of IL-2.

Antigen-specific activation increases IL-2 but not IFN-γ expression of OT-II splenocytes. (A) Culture supernatants from wild-type C57BL/6JNifdc mice, homozygous OT-II mice (Biocytogen splenocytes stimulated for 24h with medium, OVA257-264 (10 µg/mL), anti-mCD3e mAb (0.5 mg/mL) or OVA323-339 (10 µg/mL) were assayed for IL-2 and IFN-γ levels by ELISA. Data are mean ± SEM values.

The Peptide OVA323-339 Induced Immune Responses

  • OT-II mice have specific response to the OVA323-339.

Detection of OVA-induced immune responses in OT-II mice by IFN-γ ELISpot assay. Female OT-II mice from the Biocytogen were immunized with intraperitoneal injection of 0.5 mg of OVA protein (Simga, A5503-25MG) and 50 μg poly (I:C) (InvivoGen, tlrl-pic). Three weeks after the last immunization, mice were sacrificed. Mice were immunized with OVA two times at 1-week interval. One week after the last immunization, mice were sacrificed. The splenocytes were extracted, stimulated with OVA323-339, or no peptide as negative control (NC), or Cell Activation Cocktail (without Brefeldin A), (Biolegend, 42330) as positive control, and then measured for IFN-γ secretion. No significant difference in body weight among groups (Data was not shown). (A) Representative results showing stimulation of splenocytes harvested from immunized mice with negative control, or OVA323-339, or positive control in duplicates. (B) Summary of results. These data indicate that OT-II mice have specific response to the OVA323-339.

* When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [OT-II mice] (Cat# 113876) was purchased from Biocytogen.

P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →